tbuckley/cabot-search huggingface dataset:
SAT0008 Low Socioeconomic Status (SES) as Measured by Education is (NOT) Associated with Worse Outcome in Sle: Data from the 1000 Canadian Faces of Lupus
Authors: A. George, J.E. Pope
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Low socioeconomic status (SES) can affect outcomes in a chronic disease. This could be due to lack of access to healthcare including physician visits and medications and/or due to health related behaviors that may be associated with low SES. This has been demonstrated in some studies where global health care is lacking. The purpose of this study was to determine if SES affected SLE outcomes (for activity and damage) in a large Canadian cohort where there is global healthcare except that medications are not universally provided by the healthcare system. <h3>Objectives</h3> We wanted to determine whether socioeconomic status, as measured by education, had an impact on disease activity (measured by SLAM-2, SLEDAI-2K) or disease damage (measured by SLICC SDI) in patients with systemic lupus erythematosus (SLE). <h3>Methods</h3> Data was gathered from the 1000 Canadian Faces of Lupus, a multi-center, prospective cohort database and included adult SLE patients from June 2005 onward. Socioeconomic status, as measured by education was defined as being either low (did not complete high school) or high (completed high school or further). The relationship between socioeconomic status, as measured by education and SLE outcomes were evaluated using one-way ANOVA and logistic regression analyses. <h3>Results</h3> There were 484 patients who met the inclusion criteria (mean age 47 years, 91.5% female, mean disease duration of 10 years). Of the included patients, 80.4% had completed high school education or higher and 19.6% had not completed high school. One-way ANOVA analyses of education level to SLE outcomes of disease activity (SLAM-2 and SLEDAI-2K) and disease damage (SLICC) demonstrated the following: SLICC, p=1.0, SLAM-2, p=0.3 and SLEDAI-2K, p=0.011. Further logistic regression analysis of SLEDAI-2K did not demonstrate significance with multiple variables including age, p=0.8, gender, p=1.0, ethnicity, p=0.7 and disease duration, p=0.5. <h3>Conclusions</h3> Socioeconomic status, as measured by education, when adjusting for confounding variables, does not appear to have an impact on SLE patient outcomes as measured by disease activity (SLAM-2 and SLEDAI-2K) or disease damage (SLICC). This could be due to the fact that the patients enroling in a cohort have better health related behaviors and/or better education or other measures of SES than those who do not or it could be due to universal healthcare negating SES effects, or for other reasons including that SES does not currently affect outcomes in SLE. A population study of all SLE patients in a country with universal healthcare may be needed to confirm these results. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2731
Abstract 808: Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology
Authors: Lonneke Gravendeel, Mathilde Kouwenhoven, Olivier Gevaert, Johan de Rooi, Andrew Stubbs, Elza Duijm, Anneleen Daemen, Fonnet Bleeker, Linda Bralten, Nanne Kloosterhof, Bart de Moor, Paul Eilers, Peter van der Spek, Johan M. Kros, Peter Sillevis Smitt, Martin van den Bent, Pim French
Journal: Cancer Research (2010)

Abstract Gliomas are the most common primary brain tumors with heterogeneous morphology and variable prognosis. Treatment decisions in patients rely mainly on histological classification and clinical parameters. However, differences between histological subclasses and grades are subtle, and classifying gliomas is subject to a large inter-observer variability. To improve current classification standards, we have performed gene expression profiling on a large cohort of glioma samples of all histological subtypes and grades. We identified seven distinct molecular subgroups that correlate with survival. These include two favorable prognostic subgroups (median survival &amp;gt;4.7 years), two with intermediate prognosis (median survival 1-4 years), two with poor prognosis (median survival &amp;lt;1 year), and one control group. The intrinsic molecular subtypes of glioma are different from histological subgroups and correlate better to patient survival. The prognostic value of molecular subgroups was validated on five independent sample cohorts (TCGA, REMBRANDT, GSE12907, GSE4271, and Li et al.). The power of intrinsic subtyping is demonstrated by its ability to identify a subset of prognostically favorable tumors within an external dataset that contains only histologically confirmed glioblastomas. Specific genetic changes (EGFR amplification, IDH1 mutation, 1p/19q LOH) segregate in distinct molecular subgroups. We identified a subgroup with molecular features associated with secondary glioblastoma, suggesting that different genetic changes drive gene expression profiles. Finally, we assessed response to treatment in molecular subgroups. Our data provides compelling evidence that expression profiling is a more accurate and objective method to classify gliomas than histological classification. Molecular classification therefore may aid diagnosis and can guide clinical decision making. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 808.
SAT0335 Medical Comorbidity is Associated with Persistent Index Hip Pain after Primary THA
Authors: J. A. Singh, D. Lewallen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Pain is the #1 reason for patients with end-stage arthritis to undergo hip arthroplasty. More insights into factors that predict suboptimal pain outcomes after hip arthroplasty are needed to improve patient outcomes after total hip arthroplasty (THA) <h3>Objectives</h3> To characterize whether medical comorbidity predicts persistent moderate-severe pain after total hip arthroplasty (THA) <h3>Methods</h3> We analyzed the prospectively collected data from the Mayo Clinic Total Joint Registry for patients who underwent primary or revision THA between 1993-2005. Using multivariable-adjusted logistic regression analyses, we examined whether certain medical comorbidities were associated with persistent moderate-severe hip pain 2- or 5-years after primary or revision THA. Odds ratios (OR), along with 95% confidence intervals (CI) and p-value are presented. <h3>Results</h3> The primary THA cohort consisted of 5.707 THAs and 3,289 THAs at 2- and 5-years, and revision THA, 2.687 and 1,627 THAs, respectively. In multivariable-adjusted logistic regression models, in the primary THA cohort, renal disease was associated with lower odds of moderate-severe hip pain (OR, 0.6; 95% CI, 0.3, 1.0) at 2-years. None of the comorbidities were significantly associated at 5-years. In the revision THA cohort, heart disease was significantly associated with higher risk (OR, 1.7; 95% CI, 1.1, 2.6) at 2-years and connective tissue disease with lower risk (OR, 0.5; 95% CI, 0.3, 0.9) of moderate-severe hip pain at 5-years follow-up. <h3>Conclusions</h3> This study identified new correlates of moderate-severe hip pain after primary or revision THA, a much-feared outcome of hip arthroplasty. Patients with these comorbidities should be informed regarding the increased risk or moderate-severe index hip pain, so that they can have a fully informed consent and realistic expectations. <h3>Disclosure of Interest</h3> None Declared
CS-15 * NUCLEAR FACTOR I-A (NFIA) PROMOTES GBM SURVIVAL THROUGH NFkB PATHWAY
Authors: J. Lee, H.-R. Song
Journal: Neuro-Oncology (2014)

Glioblastoma (GBM) is the most common primary human malignant tumor and is almost incurable. Treatment of GBM is challenging, partly due to apoptosis evasion and drug resistance. We recently showed that Nuclear Factor I-A (NFIA), a glial fate determinant, promotes GBM malignant behavior and inhibits cell death. Our subsequent analysis showed that NFkB p65 contains an NFIA-binding motif and physically associates with NFIA. NFkB is a transcription factor that plays key roles in cell survival, resistance to cytotoxic therapy, and immune responses. Further, we showed that the levels of NFIA and NFkB are highly correlated in the primary GBM tumors. Using gain- and loss-of function approaches, we demonstrated that NFIA induces NFkB transcription and increases the level of NFkB and its downstream anti-apoptotic factors. Interestingly, NFIA expression also increases in response to ectopic NFkB or to the NFkB activator TNFa, suggesting a feed-forward effect. Moreover, both genetic and pharmacologic inhibition of NFkB blocks the anti-apoptotic effect of NFIA. Together, these data suggest that NFIA-induced survival is mediated in part by NFkB. These novel observations place NFIA at the center of a signaling network that controls GBM progression. This is the first evidence to link between NFIA and NFkB in glioma biology and thus facilitate our understanding of emerging role of NFIA in cancer, which may open new insights into therapy by targeting relevant pathways.
Stat Bite: HIV-Related Non-Hodgkin's Lymphoma
Authors: L. Fintor
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Stat Bite : HIV-Related Non-Hodgkin's Lymphoma Get access Lou Fintor Lou Fintor Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 3, 5 February 1992, Pages 143–144, https://doi.org/10.1093/jnci/84.3.143 Published: 05 February 1992
Increase in Bone Mass after Treatment of Hyperprolactinemic Amenorrhea
Authors: Anne Klibanski, Susan L. Greenspan
Journal: New England Journal of Medicine (1986)

Hyperprolactinemia occurs in 25 to 30 percent of young women with amenorrhea, and this condition is known to be associated with osteopenia. To determine whether the osteopenia is affected by treatment of hyperprolactinemia, we studied 32 women with hyperprolactinemic amenorrhea prospectively for 12 to 72 months to investigate the effects of sustained hyperprolactinemia or return of gonadal function on bone mass. We studied 18 patients using direct photon absorptiometry before and after normalization of serum prolactin levels. Initial bone densities ranged from 0.55 to 0.77 g per square centimeter (mean ±1 SD, 0.64±0.05) — densities significantly lower (P<0.001) than those of controls (0.71±0.04 g per square centimeter). After therapy, bone density increased significantly (P<0.001), to 0.67±0.05 g per square centimeter, but remained lower (P<0.05) than normal. Fourteen patients were followed without therapy. Their initial bone densities ranged from 0.62 to 0.75 g per square centimeter (mean, 0.67±0.04) — values significantly lower (P<0.02) than those in controls. There was a significant decrease (P<0.002) in bone density over time in this group. We conclude that (1) treatment of hyperprolactinemia increases bone mass in most amenorrheic women with osteopenia, (2) normalization of serum prolactin levels in such women is associated with prevention of bone loss, and (3) a subset of untreated women with hyperprolactinemia have progressive osteopenia, which could have adverse long-term health consequences. (N Engl J Med 1986; 315:542–6.)
Endoscopic pyloromyotomy: a new concept of minimally invasive surgery for pyloric stenosis
Authors: M. Kawai, S. Peretta, O. Burckhardt, B. Dallemagne, J. Marescaux, N. Tanigawa
Journal: Endoscopy (2012)

<b>Background and study aims:</b> Pyloric stenosis is currently managed using open or laparoscopic pyloromyotomy. However, with recent improvements in flexible endoscopic instrumentation and techniques, totally peroral endoscopic approaches could reduce the invasiveness of myotomic procedures. The aim of the study was to establish the feasibility and efficacy of endoscopic submucosal pyloromyotomy in a porcine model. <b>Methods:</b> Four pigs were included in a preliminary study and a 2-week survival study was performed in another four pigs. An esophagogastroduodenoscope was inserted perorally into the stomach. Saline solution was injected into the submucosal space proximal to the pylorus. The gastric mucosa was incised and a 5-cm submucosal tunnel was created. After exposure of the muscular layer in a submucosal tunnel, myotomy of the circular muscle layer was performed until the longitudinal muscular layer was reached. Once myotomy was completed, endoscopic clips were used to re-approximate the mucosal incision. <b>Results:</b> Submucosal dissection, identification of the circular muscular layer, and pyloromyotomy were achieved in all animals. Acute complications such as bleeding and perforation were not observed in any cases. Median pyloric resting pressure was reduced from 16.5 mmHg to 6.1 mmHg immediately after myotomy and 8.4 mmHg at 14 days after myotomy. <b>Conclusion:</b> Peroral endoscopic submucosal pyloromyotomy appears to be technically feasible and effective. Potential clinical applications, such as for infantile hypertrophic pyloric stenosis or delayed gastric emptying after esophagectomy, could be considered after confirmation of safety in additional survival studies.
Abstract 4369: Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in C.B-17/SCID mice by intraperitoneal administration of Clostridium Perfringens Enterotoxin (CPE)
Authors: Alessandro D. Santin, Emiliano Cocco, Stefania Bellone, Francesca Casagrande, Marta Bellone, Paola Todeschini, Joyce Varughese, Dan-Arin Silasi, Masoud Azodi, Thomas Rutherford, Peter Schwartz, Sergio Pecorelli
Journal: Cancer Research (2011)

Abstract Emerging evidence has suggested that the capability to sustain tumor formation, growth and resistance to chemotherapy in ovarian as well as other human malignancies, exclusively resides in a small proportion of tumor cells termed cancer stem cells (CSC). If this hypothesis is correct, different therapeutic approaches need to be considered for the elimination of the cancer stem cell population. During the characterization of CD44+ ovarian CSC we found a high expression of the genes encoding for claudin-4. Because this tight junction protein is the natural high affinity receptor for the cytotoxic effect of Clostridium Perfringens Enterotoxin (CPE), we have extensively investigated the sensitivity of ovarian CSC to CPE treatment in vitro and in vivo. We report that CD44+ ovarian CSC expressed claudin-4 gene at significantly higher levels when compared to matched autologous CD44- ovarian cancer cells and, regardless of their higher resistance to chemotherapeutic agents, died within 1 hr to the exposure to 1.0 μg/mL of CPE in vitro. Importantly, multiple intraperitoneal (i.p.) administration of sublethal doses of CPE in SCID mouse harboring established xenografts of chemotherapy resistant CD44+ ovarian CSC had a significant inhibitory effect on tumor progression leading to the cure and/or long term survival of all treated animals (p = 0.001). CPE may represent an unconventional, potentially highly effective strategy to eradicate chemotherapy resistant CSC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4369. doi:10.1158/1538-7445.AM2011-4369
Cancer Watch: Top News Stories of 1988
Authors: P. A. Newman
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Cancer Watch: Top News Stories of 1988 Get access Patricia A. Newman Patricia A. Newman Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 1, January 1989, Pages 11–12, https://doi.org/10.1093/jnci/81.1.11 Published: 01 January 1989
Estrogen Receptors and Responses to Chemotherapy and Hormonal Therapy in Advanced Breast Cancer
Authors: David T. Kiang, Daniel H. Frenning, Anne I. Goldman, Virginia F. Ascensao, B. J. Kennedy
Journal: New England Journal of Medicine (1978)

To determine the correlation between the estrogen-receptor status and responses to chemotherapy or hormonal therapy, we retrospectively analyzed the clinical data of 143 patients with advanced breast cancer. Receptor contents were determined by a sucrose-gradient method and designated arbitrarily as "rich" or "poor." The response rate to chemotherapy was significantly higher in receptor-rich tumors (86 per cent) than in receptor-poor tumors (36 per cent) (P<0.001). Patients with receptor-rich tumors also responded favorably to hormonal therapy. However, there was no correlation between the responses to hormonal therapy and to chemotherapy when they were used sequentially, a phenomenon that may be attributed to the changes in tumor receptor content during the clinical course. These data suggest that separate factors associated with the response to chemotherapy may coexist with estrogen receptors in breast cancer. (N Engl J Med 299:1330–1334, 1978)
807 APPLICATION OF LNP01-FORMULATED SIRNAS IN VIVO ACTIVATES HEPATIC TOLL-LIKE RECEPTORS VIA MYD88-DEPENDENT PATHWAYS WHICH CAN BE CONTROLLED BY CHEMICAL RIBOSE MODIFICATIONS
Authors: C.I. Real, R. Broering, K. Jahn-Hofmann, L. Ickenstein, M. John, K. Kleinehr, G. Gerken, J.F. Schlaak
Journal: Journal of Hepatology (2012)
Outcome of breast cancer in young women stratified by age at diagnosis: the younger, the worse? The Korean Breast Cancer Society registry program data.
Authors: W Han
Journal: Cancer Research (2009)

Abstract Abstract #2079 Introduction: In the previous studies investigating the relation between age of onset of breast cancer and disease outcome, the age cut-off for very young onset was usually under 35 or under 40. However, these cut-offs were set arbitrarily or empirically without sufficient outcome data on the detailed age strata. Hence we tried to compare breast cancer outcomes of premenopausal women (age ≤50)according to age groups of 5 year interval.&amp;#x2028; Patients and Methods: We analyzed data of 9,885 breast cancer patients aged ≤50 years registered in the Korean Breast Cancer Society Registration Program between 1992 and 2001. The overall survivals were compared between age groups. The median follow-up for this cohort of patients was 74.4 months.&amp;#x2028; Results: 351 patients were aged &amp;lt;30 years (Group I), 1,092 patients were 31-34 (Group II), 2,087 patients were 35-39 (Group III), and 6,354 patients were 40-50 years old (Group IV). Younger patients had significantly higher T-stage, higher lymph-node positivity, and lower hormone-receptor positiviy than older patients. In Univariate analysis, Group I patients showed worse outcome than Group II patients (p=0.03). Also, Group II patients showed worse outcome that Group III patients (p&amp;lt;0.0001). Interestingly, there was no significant difference in survival of Group III and Group IV patients. This survival trend according to age group was found only in hormone receptor positive or unknown patients, and not in hormone receptor negative patients. Multivariate analysis was performed using a Cox regression model including age groups, tumor size (2cm), lymph node involvement, hormone receptor, chemotherapy, and hormone therapy. Compared to the Group IV patients (reference), Group III patients had similar survival (hazard ratio (HR) = 1.06, 95% confidence interval (CI): 0.94-1.20). But, Group II and I patients had significantly worse survival (HR = 1.43 (95%CI: 1.24-1.64), HR = 2.09 (95%CI: 1.69-2.58), respectively). The HR was even higher in patients young than 25 (HR = 2.35, 95%CI: 1.35-4.06).&amp;#x2028; Conclusions: Patients aged 35 to 39 showed similar overall survival compared to patients aged 40 to 50, whereas patients aged &amp;lt;35 showed significantly worse outcome than patients aged 35 to 39. Moreover, patients aged &amp;lt;30 showed significantly worse outcome than patients aged 31 to 34. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2079.
P75 Impaired cardiorespiratory reserve in primary biliary cirrhosis patients undergoing liver transplant assessment
Authors: J. Prentis, D. E. Jones, M. I. Trenell, C. P. Snowden
Journal: Gut (2011)

<h3>Introduction</h3> It has been previously shown that PBC patients have bioenergetic abnormality in both peripheral and cardiac muscle. In particular they exhibit significantly lower cardiac muscle phosphocreatine-to-ATP ratio (measure of cardiac bioenergetic integrity) compared with control subjects. In other disease settings, such as cardiac failure, changes of this type have been associated with impaired cardiac function and increased risk of cardiac death. <h3>Aim</h3> The objective of the present study was to examine whether these changes are reflected in systemic measurements of cardiopulmonary reserve determined by a non-invasive cardiopulmonary exercise test (CPET). <h3>Method</h3> Consecutive PBC patients being assessed for liver transplantation underwent CPET. The test was conducted in a consistent environment and reviewed by a trained physician to determine objective measures of cardiorespiratory reserve. A control group of consecutive patients with primary sclerosing cholangitis (PSC), also being assessed for liver transplantation was also tested. We compared the results of CPET of all patients with a diagnosis of PBC with those with PSC. Patient demographics and MELD scores at assessment were also collected. A non-paired t test was used to determine group differences. <h3>Results</h3> In total, 38 patients had a diagnosis of either PBC or PSC. Three patients (2 PBC and 1 PSC) did not exercise sufficiently to gather meaningful results and were excluded from the analysis. The PSC patients assessed for transplantation had significantly worse liver disease as assessed by the MELD score. However, all measures of cardiorespiratory reserve derived from CPX testing were significantly lower in the PBC group. There was no statistical difference between the two groups with respect to age, thus excluding age as the underlying factor in decreasing their fitness. <h3>Conclusion</h3> In this cohort, patients with PBC, despite having lower MELD scores and equivalent age at transplantation assessment, had significantly impaired cardiorespiratory reserve, when compared to patients with PSC. The results add to the evidence that there is a specific PBC-related bioenergetic effect due to the immunology of PBC that is absent in PSC. This finding could have significant relevance on both future studies and treatment regimes to improve cardiovascular fitness.